India Proposes Central Oversight of Antimicrobials

India Proposes Central Oversight of Antimicrobials

On 19 November 2026, the Ministry of Health and Family Welfare proposed stricter central regulatory oversight of antimicrobial drugs by amending the New Drugs and Clinical Trials Rules, 2019. The proposal is intended to strengthen checks on their quality, safety and efficacy and help address antimicrobial resistance (AMR).

Proposed amendment and licensing process

Draft Gazette Notification G.S.R. 983 (E), dated 6 November 2026, proposes adding “antimicrobials” to the definition of “New Drug” under Rule 2(1)(w)(v). Manufacturers would first need permission from the Central Licensing Authority before applying to the relevant State Licensing Authority for a manufacturing licence. The Ministry cited concerns that antimicrobial manufacturing licences have been granted without sufficient scrutiny, including bioavailability and bioequivalence and stability studies.

Public consultation

The Ministry said inadequate assessment can compromise antimicrobial quality, safety and efficacy, while substandard products can contribute to the development and spread of AMR and put patients at risk. The draft invites objections and suggestions from stakeholders and the public before the Central Government finalises the changes. The proposal aligns with global efforts against AMR and the One Health approach emphasised in the G20 New Delhi Leaders’ Declaration.

Important Facts for Exams

  • Treatment and prevention: Antimicrobial medicines used to treat infections are classed as antimicrobial chemotherapy, while those used to prevent infection are antimicrobial prophylaxis.
  • Resistance mechanisms: Antimicrobial resistance can arise through spontaneous mutation or horizontal gene transfer, which can spread resistance genes between bacterial species.
  • WHO AWaRe classification: WHO groups antibiotics into Access, Watch and Reserve categories to support stewardship, with Reserve agents intended for limited use against difficult-to-treat infections.
  • Scope of AMR: Antibiotic resistance is one part of antimicrobial resistance, which also includes resistance to antifungal, antiviral and antiparasitic medicines.

Leave a Reply

Your email address will not be published. Required fields are marked *